Heartflow, Inc. Common Stock (NASDAQ: HTFL) — Reimbursement Opens the Market, Not the Moat

Published: 2026-09-11 · Verdict: Reduce · Entry price: $32 · Price target: $39 · Research confidence: High (89%)

Executive conclusion

Analyst Take

At the September 11, 2026 close of $48.08, the appropriate stance is REDUCE, with a twelve-month price target of $39 and a preferred entry price near $32. The target applies approximately 10 times estimated 2027 revenue, adds estimated net cash, and allows for continuing share issuance. The entry level corresponds to roughly eight times the same base-case revenue estimate. Both multiples remain generous for a company with negative GAAP operating income and free cash flow, but they recognize Heartflow’s exceptional growth, improving gross margin, clinical evidence, balance-sheet strength, and head start in advanced coronary computed-tomography analysis.

The operating achievement is real. Revenue increased from $87.2 million in 2023 to $176.0 million in 2025, a two-year compound growth rate of approximately 42%. Gross margin rose from 66.6% to 76.8%, and first-half 2026 revenue advanced 45% to $116.7 million. Q2 revenue was $64.1 million, up 48%, while GAAP gross margin reached 83.0%. Management consequently raised 2026 revenue guidance for the second time, to $246-$250 million. The IPO, conversion of pre-IPO securities, and repayment of term debt left $246.8 million of cash and investments and no funded borrowing at June 30, 2026. These are reported facts, not projections. [S1][S2][S3]

Heartflow also has genuine clinical and commercial assets. FFRCT adds lesion-specific physiology to an existing coronary CT angiogram without another scan or an invasive pressure wire. Plaque Analysis quantifies plaque burden and composition. RoadMap and PCI Navigator extend the workflow toward anatomical review and procedure planning. The FUSION randomized trial found that an FFRCT-guided strategy reduced invasive angiography that revealed no obstructive disease from 33% to 18%. Heartflow has accumulated regulatory experience, payer relationships, workflow integrations, an extensive publication record, and more than 1,800 institutional relationships according to company materials. [S3][S7][S8]

The central investment objection is that the equity price capitalizes durable ownership of this emerging category before Heartflow has shown durable company-specific economics. At the current price and approximately 87.0 million shares, market capitalization is about $4.18 billion. After cash, investments, and lease liabilities, enterprise value is approximately $3.96 billion, or 16.0 times midpoint 2026 guidance and 18.7 times trailing revenue. Heartflow is still producing GAAP operating losses, free-cash-flow deficits, material stock compensation, and negative accounting ROIC. Hinge Health and Tempus AI—imperfect but useful high-growth healthcare references—trade at approximately 8.7 and 7.7 times trailing revenue, respectively. Heartflow’s superior current growth supports a premium, but not immunity from a major reset if growth merely normalizes. [S2][S16]

The newest competitive evidence weakens any claim that reimbursement or regulatory clearance belongs uniquely to Heartflow. Cleerly received FDA clearance for its next-generation plaque product in July 2026 and markets both the plaque and ischemia CPT codes. Keya Medical’s cleared FFR-CT product used Heartflow FFRct as its predicate. The codes can expand the category while simultaneously making it easier for competitors to present an economic case to providers. Heartflow still has the stronger visible combination of evidence, installed workflows, and payer history, but the moat is a lead in evidence and execution—not ownership of the procedure, code, or clinical concept. [S10][S11][S12]

Reported operating metrics require similar skepticism. Q2 cases grew 74% while revenue grew 48%. Heartflow counts FFRCT and Plaque analyses from the same CCTA as two cases, so cases do not equal unique scans or patients. Simple revenue per case fell approximately 15.5% year over year. That does not prove FFRCT price declined by the same amount: Plaque mix, office and clinic pricing, rebates, and double-counting all affect the calculation. It does establish that headline case growth overstates the growth of the revenue denominator investors ultimately own. [S2][S13]

The strongest counter-case is that this skepticism arrives just before operating leverage becomes visible. The 2025 account cohort is still maturing; Plaque reimbursement only became effective in 2026; automation could sustain gross margins near management’s mid-80s objective; and free workflow products may deepen ordering habits. If Heartflow remains the default analytical layer as CCTA takes share from stress testing, the present losses could represent unusually productive category investment. Management’s September conference comments also suggested that Plaque could eventually exceed FFRCT and that broader commercial coverage could lift covered lives into the mid-80% range, although those are management expectations rather than achieved economics. [S13][S14]

Conviction is higher in the valuation warning than in a definitive adverse view of the franchise. Filing evidence is strong for historical revenue, margins, cash, dilution, case definitions, legal proceedings, and current guidance. Evidence is weaker for product-level paid analyses, realized prices, claim denials, customer retention, matched-account utilization, competitive wins and losses, and fully allocated contribution. Only one current post-IPO earnings-call transcript was available through Company Financials; the Q1 release and September management conference supplement it but do not replace missing cohort disclosure.

The next decision sequence is concrete. Evidence that would improve the call includes sustained revenue growth above 30%, retained Plaque ordering after the reimbursement anniversary, product-adjusted price stability, four quarters of post-stock-compensation operating leverage, moderated dilution, and resolution of the DOJ matter without commercial restrictions. Evidence that would worsen it includes growth below the mid-20s before cash breakeven, declining FFRCT revenue in matched accounts, gross margin below 80%, competitive displacement at major systems, higher denial rates, reaccelerating cash use, or an adverse legal resolution. The investment is therefore not a dispute about whether Heartflow has a useful product. It is a dispute about whether clinical usefulness, category growth, and gross margin will become durable per-share cash returns quickly enough to justify an already exceptional multiple.

Stock Price Action — Five-Year Event Map

A genuine five-year public-price record does not exist. Heartflow completed its IPO in August 2025, leaving only about thirteen months of public trading through the controlled report date. Private financing prices are not comparable to exchange trading and should not be spliced into the series.

The offering was priced at $19 per share, while the first public close was $28.75. Through September 11, 2026, the available intraday range was $20.13 to $51.78, and the current $48.08 close sat approximately 88% of the way from the low to the high. It was about 7% below the high, 139% above the low, 67% above the first close, and 153% above the IPO price. Those are price facts; they neither establish intrinsic value nor prove a moat. [S16][S21]

• August 2025—IPO and immediate scarcity premium. Heartflow sold 16.7 million base-offering shares at $19 before the underwriters’ option, raising approximately $316.7 million gross. The first-day close of $28.75 was about 51% above the offering price. A reasonable interpretation is that investors valued scarce pure-play exposure to coronary AI and the accompanying balance-sheet repair, but the move occurred before public investors had observed a full quarter. [S16][S21]

• September 23, 2025—14.1% advance after product and coverage news. The move followed Heartflow’s announcement of FDA clearance and launch of its next-generation Plaque Analysis and Cigna coverage effective October 1. The temporal relationship supports an event attribution, although the exact contribution of clearance, coverage, and momentum cannot be separated. [S16][S17]

• November 13, 2025—13.4% decline following Q3 results. Q3 revenue still grew approximately 41% to $46.3 million, but the company remained loss-making and reported a large noncash warrant-remeasurement expense. The price decline is factual; attributing it specifically to losses, warrant noise, or normalization of the IPO premium remains interpretation. [S5][S16]

• February 12-13, 2026—16.5% daily decline and subsequent low. The stock closed at $22.49 on February 12 and reached the public-history intraday low of $20.13 on February 13. No reviewed primary filing supplies a clean company-specific cause. The move should remain unattributed instead of being retrofitted to a competitive or reimbursement narrative. [S16][S20]

• March 18-19, 2026—results-period recovery. The shares rose 13.1% on March 18 before the after-market annual-results release and added only 1.6% the next day. It would therefore be inaccurate to call the March 18 move a reaction to results. The release did provide initial 2026 guidance of $218-$222 million, reported continued growth and gross-margin improvement, and framed Plaque reimbursement as a new catalyst, but the intraday sequencing prevents confident causality. [S16][S20]

• May 15, 2026—12.2% decline after Q1 despite a guidance increase. Heartflow reported 41% first-quarter revenue growth and raised guidance to $228-$232 million, while GAAP operating loss included a $7.5 million facility impairment and growth spending remained high. The negative reaction suggests that headline growth was already expected or that investors focused on losses and cash use, but that explanation remains inferential. [S2][S4][S16]

• June 30, 2026—15.8% decline without an identified material disclosure. No contemporaneous primary company filing reviewed provides a satisfactory causal explanation. This is useful evidence about the stock’s short-history volatility, not about a hidden business event. [S16][S20]

• August 14, 2026—35.7% increase after Q2. Heartflow reported 48% revenue growth, 83.0% GAAP gross margin, $7.8 million of Plaque revenue, and raised annual guidance to $246-$250 million. The timing makes the results and guidance the most defensible explanation for the move, while the allocation among the revenue beat, Plaque acceleration, margin, and positioning cannot be measured. [S2][S3][S16]

• Late August and early September—new high following clinical evidence and continued re-rating. FUSION was published on August 27, and the shares reached $51.78 intraday on September 2. The study strengthened the clinical case, but the stock did not make an isolated publication-day move commensurate with the entire advance. It would be excessive to attribute the new high solely to FUSION. [S7][S16]

The short record makes conventional five-year momentum, drawdown, and own-history valuation-percentile claims impossible. It also makes anchors unusually fragile. The IPO price was an underwriting transaction, the first close contained scarcity and allocation effects, and the February low occurred before Plaque contributed meaningful revenue. The most decision-useful conclusion is that the stock re-rated much faster than the earnings base: the August gap lifted trailing EV/sales from approximately the low teens toward 19 times without changing the absence of operating profit.

Verdict: Price action confirms high sensitivity to company events, especially guidance, but does not confirm durable market power. Repeated double-digit moves, two large unattributed declines, and only thirteen months of history are disconfirming evidence against treating the current quote or recent momentum as a stable consensus valuation. [S3][S16]

Business Overview

Heartflow is a software-as-a-medical-device company, not a conventional subscription-software vendor and not an imaging-equipment manufacturer. A hospital, imaging center, or cardiology practice performs a coronary computed-tomography angiogram and uploads the images to Heartflow’s cloud workflow. Heartflow processes the study using software, computational models, quality controls, and—where still required—trained personnel, then returns one or more analyses. Customers do not need to buy dedicated capital equipment from Heartflow. Revenue is recognized when an ordered analysis is delivered. [S1][S2]

The product suite addresses related decisions from one CCTA. RoadMap organizes coronary anatomy and is generally supplied without a separate price. FFRCT estimates pressure changes across lesions and helps determine whether an apparent anatomical narrowing is physiologically important. Plaque Analysis quantifies plaque volume and composition. PCI Navigator uses CCTA and FFRCT information to support pre-procedure planning. Plaque Staging translates burden into a classification, while Plaque Tracker is intended to support longitudinal comparisons beginning in 2027. [S2][S13]

The customer value proposition is straightforward but should be segmented. FFRCT can add functional information without another scan or an invasive pressure wire. Plaque can characterize disease burden that visual stenosis alone may miss. RoadMap can improve review and communication, and PCI Navigator may reduce uncertainty before intervention. The benefits can include better patient selection, fewer unnecessary invasive angiograms, a more complete CCTA service, and reimbursable advanced analysis. The FUSION trial supports the avoided-procedure claim but did not establish lower total cost, better quality of life, more revascularization, or fewer major adverse events over the reported horizon. [S7]

Revenue is recurring in behavior but transactional in contract: substantially all sales arise only when a physician orders and Heartflow delivers an analysis, with no disclosed subscription backlog. Productive accounts can order repeatedly and established workflows may make revenue operationally recurring. Nevertheless, Heartflow remains exposed to CCTA volume, physician decisions, image quality, payer criteria, claim payment, customer budgets, rebates, and competitive routing on each study. Pay-per-use lowers the adoption barrier but provides less contractual protection than a prepaid multi-year subscription. [S1][S2]

FFRCT remains the economic center. The 2025 annual filing said approximately 98% of revenue was associated with FFRCT. Plaque was only about $1.5 million of 2025 revenue according to later management commentary, then accelerated to $3.2 million in Q1 and $7.8 million in Q2 2026 following the new Category I code. RoadMap and PCI Navigator are currently strategic workflow products rather than separately disclosed revenue lines. The platform narrative is plausible, but reported revenue had not yet become broadly diversified by product. [S1][S13][S14]

Case counts are analyses, not scans or people. Heartflow counts an FFRCT result and a Plaque result ordered from one CCTA as two cases. Q2 2026 cases rose 74% to 84,491, while revenue rose 48% to $64.1 million. Simple revenue per reported case fell from approximately $897 to $758, a decline of about 15.5%. The calculation is a valid consolidated mix diagnostic but not a pure measure of FFRCT price because it blends products, sites, rebates, and potentially two paid analyses from one source scan. [S2][S13]

The filing supplies a useful case history: 28,803 in Q1 2024, 33,039 in Q2, 34,970 in Q3, 37,805 in Q4, 40,336 in Q1 2025, 48,423 in Q2, 51,805 in Q3, 57,776 in Q4, 67,443 in Q1 2026, and 84,491 in Q2. This sequence confirms strong growth, but not its decomposition between new scans, added products per scan, new accounts, and utilization at established accounts. [S2]

The business can be understood through five drivers: CCTA scan growth, account activation, analyses per account, product mix and realized price, less the human-review, cloud, selling, research, and compliance costs required to deliver those analyses. Management discloses cases, selected activation measures, revenue, and gross margin. It does not disclose product-level paid claims, realized prices, denial rates, retention, net revenue retention, customer-acquisition cost, matched-account revenue, or fully allocated product contribution. The operating model is understandable; the cohort economics remain partly hidden.

The channel mix is changing. Office and clinic settings accounted for approximately 22% of U.S. cases in 2023, 28% in 2024, 32% in 2025, and about 36% in the first half of 2026. Distributed imaging can widen patient access and addressable accounts, but the filing and call identify lower average selling prices and volume rebates as offsets to volume growth. The economically relevant metric is contribution per unique scan, not cases alone. [S1][S2][S13]

The United States dominates. The 10-K reported approximately 92% of 2025 revenue from U.S. customers. On the 10-Q’s billing-address basis, Q2 2026 U.S. revenue was $60.3 million and international revenue $3.8 million. The release used a slightly different operational geography split, so filing geography is preferable for reconciliation. No customer represented more than 10% of consolidated revenue, reducing individual-account concentration, although a health system or regional payer can affect many sites simultaneously. [S1][S2][S3]

Heartflow has substantial assets that accounting does not capitalize fully. The December 2025 filing cited approximately 160 million annotated CCTA images, while 2026 management materials increased the figure to more than 200 million. It also has clinical studies, publications, regulatory files, patents, payer work, quality systems, trained review processes, and integrations. These resources can shorten product development, reinforce clinician trust, improve automation, and make procurement easier. Their economic value must ultimately appear in accuracy, turnaround, retention, price, coverage, selling efficiency, or contribution margin.

Economically valuable but incompletely recognized assets include Heartflow’s clinical evidence, annotated coronary-image data, regulatory files, patents, payer relationships, workflow integrations, and trained production processes; their value depends on continuing adoption rather than their record count alone. Competitors can build different datasets, secure their own clearances, use predicate pathways, and compete under the same codes. A large dataset is evidence of replication difficulty, not by itself evidence of monopoly economics. [S1][S11][S12]

The security itself is uncomplicated. The security is ordinary U.S. corporate common stock, not an ADR, partnership, MLP, or K-1 issuer. Heartflow is a Delaware corporation listed on Nasdaq. It has declared no dividend, and investors should expect ordinary Form 1099 treatment for any future distributions rather than partnership reporting. [S1][S21]

Verdict: Heartflow combines low customer capital requirements, repeat ordering, clinically useful analysis, and high incremental gross margin. The disconfirming evidence is that contractual revenue remains transactional, FFRCT still dominates sales, case growth overstates unique-scan growth, channel mix pressures realized revenue, and the cohort data needed to prove retention and contribution are not public. [S1][S2]

Industry Dynamics

Heartflow operates at the intersection of coronary diagnosis, radiology, cardiology, regulated medical software, cloud infrastructure, and reimbursement. The serviceable market is not the prevalence of coronary disease. It is the series of patients who receive an appropriate CCTA, whose images are technically adequate, whose clinicians order an additional analysis, whose payer covers it, and whose provider finds the remaining economics attractive. Each stage can expand, but each can also break the conversion from epidemiology to revenue.

Guidelines support the CCTA funnel. U.S. and European guidance has elevated CCTA in appropriate stable chest-pain and coronary-disease pathways, and the 2026 expert consensus describes CT-derived fractional flow reserve as useful when anatomical findings leave uncertainty and the result can change management. It also emphasizes image quality, appropriate patient selection, and integration with clinical judgment. Importantly, professional guidance generally validates the modality rather than a specific commercial vendor. [S8]

CCTA still competes with stress echocardiography, SPECT, PET, cardiac MRI, invasive angiography, and ordinary CCTA interpretation. Hospitals and specialists have sunk investments in scanners, nuclear cameras, laboratories, staff, referral habits, and reimbursement processes. Heartflow frequently needs CCTA to win a place in the pathway before it competes against another software vendor. That distinction allows Heartflow and direct rivals to grow simultaneously if CCTA takes share from established testing.

Management estimates a current U.S. addressable market of approximately $5 billion, with roughly $3 billion attributed to FFRCT and $2 billion to Plaque. It also estimates approximately $6 billion of future opportunity among high-risk asymptomatic patients: about $3 billion in calcium-score populations, $1 billion among patients with prior myocardial infarction or PCI, and $2 billion among patients with previously identified plaque. These figures are management estimates, not observed reimbursable revenue pools. [S13][S14]

The current market is growing because CCTA penetration, clinical acceptance, installed workflows, and reimbursement are expanding, but the quoted approximately $5 billion U.S. market and $6 billion adjacency are management estimates rather than observed revenue pools. Management estimates that CCTA represents only about 11% of U.S. noninvasive cardiac testing and grows roughly 20%, and Heartflow’s 2025 U.S. patient volume represented less than 2% of its broad opportunity. Low penetration can mean runway; it can also mean that workflow inertia, scanner capacity, training, payer rules, and referral behavior remain significant barriers. [S1][S14]

The three asymptomatic trials illustrate the gap between addressable disease and commercial market. Management plans studies of approximately 300-500 patients each beginning in late 2026 or early 2027. The disclosed objectives emphasize changes in clinical decisions at 90 days and measures such as LDL or plaque progression at 18 months. At the September conference, an interviewer challenged the absence of a hard-outcome study comparable to a competitor’s approach. Management argued that its design was faster, more capital-efficient, and more likely to support reimbursement. That is a strategy claim, not proof that payers or guidelines will accept decision change instead of hard outcomes. [S14]

Demand is overwhelmingly domestic today. U.S. revenue was approximately 92% of 2025 sales, and U.S. growth materially exceeded international growth in Q2 2026. International opportunity requires country-specific approval, reimbursement, health-technology assessment, privacy compliance, language support, and health-system procurement. Management said approximately 90 cents of each investment dollar is currently directed to the United States, confirming that international expansion is not the near-term growth engine. [S1][S2][S14]

The direct software market now includes several credible participants. Cleerly markets plaque and ischemia analysis and displays the same Category I codes that support Heartflow’s products. More importantly, the FDA cleared Cleerly’s next-generation Plaque product in July 2026, a fresh regulatory event that weakens any stale assumption that its offering remained merely aspirational. Keya Medical obtained clearance for DeepVessel FFR using Heartflow FFRct as its predicate. Elucid offers a cleared plaque-characterization product. Private-company disclosure is limited, so clearance does not prove commercial share or equal clinical evidence, but it does prove that entry is possible. [S10][S11][S12]

Competition is becoming more intense on the supply side because attractive reimbursement and improving AI tools invite new software capacity, even as regulatory evidence, payer access, integration, and physician trust keep entry from being frictionless. Once cleared and integrated, software capacity can scale faster than scanner manufacturing. Category I coding makes provider economics easier to explain and can enlarge demand, but also signals an addressable profit pool to entrants.

The industry’s profit pool is divided among scanner manufacturers, imaging providers, interpreting physicians, hospitals, cardiologists, software vendors, and payers. A Medicare allowable amount is not Heartflow’s selling price. Facility and professional splits, geography, commercial contracts, bundling, denials, customer rebates, and provider costs intervene. Cleerly’s published reimbursement guidance shows provider-level amounts under the same codes, reinforcing why reimbursement should not be treated as vendor revenue. [S9][S10]

Reimbursement has become more favorable but remains variable. CPT 75577 became effective for coronary plaque analysis in 2026. Heartflow’s annual filing describes access across all seven Medicare Administrative Contractor regions, while clarifying that five had final favorable local coverage determinations and two handled claims case by case. That is not necessarily a contradiction: coverage access and a final affirmative policy are different standards. The conservative representation is five final favorable policies plus case-by-case treatment elsewhere. Management later estimated approximately 78% covered lives and suggested Anthem could add another eight to nine percentage points, but timing was unknown. [S1][S13][S14]

CMS policy is not permanent. The 2026 Physician Fee Schedule is final, while the 2027 schedule was still proposed at the report date. Changes can affect payment amounts, site economics, eligible settings, documentation, and relative value. Commercial payers can impose their own medical-necessity criteria. Investors should model coverage, collection, and provider economics as variables rather than proprietary rights. [S9][S22]

Industry profitability is potentially high for scaled software vendors, but only a handful of direct competitors matter today and the barriers are FDA clearance, clinical validation, image data, reimbursement, integrations, sales access, and trusted turnaround—not ownership of a unique billing code. Heartflow’s 83% quarterly gross margin demonstrates an attractive gross-profit pool. Its operating losses demonstrate that clinical studies, commercial coverage, software development, compliance, support, and public-company costs absorb much of that pool. [S2][S11]

Regulation is both a moat and a source of nonlinear downside. These products are regulated medical devices. Material algorithm changes may require submissions, validation, or a predetermined change-control plan. Performance must remain reliable across scanner vendors, sites, image quality, disease patterns, and patient groups. Privacy, cybersecurity, healthcare-fraud, billing, and anti-kickback rules add obligations beyond device clearance. An established quality system helps incumbents, but a recall, inspection issue, data breach, or adverse reimbursement review can impair adoption quickly. [S1][S2]

Low-cost foreign production is a limited direct threat, but lower-cost globally developed algorithms and remote clinical-processing labor could pressure price once competitors satisfy U.S. clearance, evidence, security, and reimbursement requirements. Heartflow’s automation can counter labor-cost pressure. Keya’s clearance demonstrates that a non-U.S.-origin developer can enter the FDA pathway, although clearance alone does not establish a scaled U.S. commercial threat. [S2][S12]

The supply-side capital cycle is therefore mixed. Demand growth, codes, and high gross margins encourage entry and capital formation. Clinical evidence, payer access, physician trust, and integrations slow that entry. The likely industry outcome is neither immediate commoditization nor permanent monopoly, but a small number of regulated platforms competing for accounts and clinical mindshare while the overall CCTA market expands.

Verdict: Industry demand is structurally favorable, and guidelines plus reimbursement can expand the funnel for years. The disconfirming capital-cycle evidence is that the same reimbursement visibility attracts competitors, the codes are shared, established testing pathways retain sunk-cost advantages, and international reimbursement prevents a simple conversion from global disease prevalence to sales. [S8][S10][S11]

Competitive Position

Heartflow’s competitive advantage resides in the system around its algorithms. It began U.S. commercialization of FFRCT in 2014, has regulatory experience across multiple versions, and has built payer relationships, integrations, sales coverage, clinical publications, and production processes. Company materials cite more than 1,800 institutional relationships globally. A challenger must do more than train a model: it must validate performance, clear a device, transfer images securely, return dependable results, train physicians, negotiate contracts, support claims, and operate at clinical-service standards. [S1][S3]

Evidence is the strongest visible differentiator. FUSION randomized 528 patients with 50%-90% stenosis on CCTA. Invasive angiography without obstructive disease occurred in 18% of the FFRCT group and 33% of usual care, with an odds ratio of 0.46 and p-value below 0.001. Overall angiography was also lower in a post hoc analysis. These results can reinforce clinician and payer confidence that FFRCT improves patient selection. [S7]

The same trial limits an expansive moat claim. Revascularization was 20% in both groups, and reported quality of life, cost, and major adverse cardiovascular events did not differ. Event rates were low and the trial may not have been powered for rare outcomes, but public evidence presently supports diagnostic efficiency more strongly than hard outcomes, total-cost savings, or vendor pricing power. [S7]

Heartflow’s data scale can support training, quality assurance, and automation. The company cited approximately 160 million annotated images at December 2025 and more than 200 million later in 2026, along with hundreds of publications and studies. The change is a timing update, not necessarily inconsistent disclosure. Economic value would appear through superior accuracy, fewer rejected studies, shorter turnaround, broader indications, higher retention, lower processing cost, or pricing power. None of those outcomes follows automatically from image count. [S1][S13]

Brand matters in a clinical rather than consumer sense. The brand matters economically as a clinical-trust, payer-evidence, and procurement credential, but its value must appear in retention, share, coverage, price, or lower selling cost rather than awareness alone. Physicians and health systems may prefer an established result when it influences invasive care. Patients rarely select the analysis vendor directly, and procurement teams can evaluate alternative cleared products. Management describes high win rates and leadership but has not published an independent market-share denominator. [S13][S14]

The new Cleerly clearance sharpens the competitive test. Cleerly now has FDA-cleared next-generation plaque analysis and markets both plaque and ischemia codes. Keya’s FDA record explicitly identifies Heartflow as the predicate for its FFR-CT product. Predicate use can reflect Heartflow’s category leadership while simultaneously showing that the regulatory framework permits substantially equivalent entry. Heartflow does not own CCTA scanners, DICOM standards, the general concepts of plaque quantification or CT-derived physiology, or vendor-neutral CPT codes. [S10][S11][S12]

Competition occurs first between CCTA and established stress-testing pathways, then among software vendors on clinical evidence, product breadth, turnaround, workflow integration, payer coverage, service, and net price. This ordering explains why Heartflow can grow rapidly without proving share gains against Cleerly. It also means a direct competitor can gain accounts while Heartflow continues reporting high growth if the category expands fast enough. Independent share, matched-account utilization, and win-loss data are needed to distinguish market growth from competitive capture. [S8][S13]

The multiproduct strategy may deepen workflow dependence. RoadMap is broadly supplied, FFRCT answers functional significance, Plaque quantifies disease burden, and PCI Navigator moves downstream toward procedure planning. Plaque Staging and Tracker add longitudinal potential. Products sharing one source image and interface can lower incremental adoption friction and increase analyses per scan. The counterpoint is that RoadMap and PCI Navigator currently carry no separately disclosed revenue, and management said PCI Navigator has no reimbursement plan. Product breadth can create engagement without immediately creating contribution. [S2][S13]

Customer switching costs are operational and evidentiary rather than contractual: integrations, security review, physician training, payer confidence, and established ordering habits create friction, while pay-per-use pricing and common CPT codes preserve the ability to test or multi-source alternatives. Heartflow has not disclosed contract duration, minimum volume, renewal rates, net revenue retention, or the number of accounts using multiple vendors. The evidence supports moderate switching friction, not hard lock-in. [S1][S10]

Account cohorts are a potential advantage. Management said 340 U.S. accounts were added during 2025 and that FFRCT accounts generally take about twelve months to approach mature utilization. If true, that provides an embedded growth source independent of new wins. Yet aggregate cases cannot prove the cohort claim because Plaque double-counting, overall CCTA growth, and product mix can produce similar reported growth. Matched-account revenue and unique scans would be the appropriate tests. [S13]

Channel expansion has strategic value and economic ambiguity. Offices and clinics broaden access and can make CCTA more convenient, but they also produce lower realized prices and rebates. Distributed settings may need more integrations and commercial support. The increasing office mix should be credited as penetration evidence and debited for its effect on revenue per analysis until contribution by channel is disclosed. [S2][S13]

Patents could strengthen the position, but litigation remains unresolved. Heartflow sued Cleerly in April 2026 alleging infringement of six patents covering plaque and ischemia technology and seeking damages and injunctive relief. A complaint is an allegation, not a finding of infringement, validity, or entitlement to an injunction. Successful enforcement could raise a rival’s cost or narrow its product; an adverse ruling could weaken a perceived barrier. Alternative technical designs may preserve competition even after a Heartflow victory. [S2]

The DOJ investigation is not a conventional competitive factor, but it can affect selling practices that support the installed base. The civil investigative demands concern financial and contractual arrangements with providers and sales and marketing practices under the False Claims Act and Anti-Kickback Statute. No adverse finding has been announced. Management says the matter is not distracting operations, but that is not independent evidence of immateriality. [S1][S2][S13]

Verdict: Heartflow has the strongest visible combination of history, clinical evidence, payer access, product breadth, and installed workflow in an emerging category. The evidence supports a lead, not an impregnable moat: cleared rivals exist, Cleerly’s July 2026 clearance is fresh contrary evidence, codes are shared, switching is not contractual, and independent share and retention data are absent. [S7][S11]

Growth History and Forward Opportunities

Heartflow’s growth history is exceptional. Revenue increased from $87.2 million in 2023 to $125.8 million in 2024 and $176.0 million in 2025. Gross profit increased from $58.1 million to $94.4 million and then $135.2 million. First-half 2026 revenue was $116.7 million, 45% above the prior-year period, while reported cases rose from 88,759 to 151,934. [S1][S2]

Growth comes from overlapping sources: CCTA adoption, new account installation, utilization ramps, additional analyses per scan, Plaque reimbursement, office and clinic penetration, payer coverage, and contractual pricing. Public evidence does not provide a clean bridge. The distinction matters because new-account maturation can recur, while a reimbursement launch can create a step-up; product cross-sell can lift gross profit per scan, while lower-priced channel mix can depress revenue per case.

Management began 2026 with revenue guidance of $218-$222 million. After Q1 it increased the range to $228-$232 million. Following Q2 it raised guidance again to $246-$250 million, implying 40%-42% annual growth. Plaque guidance moved to $29-$31 million and approximately 1,250 activated accounts. At the midpoint, second-half revenue must be approximately $131.3 million after $116.7 million in the first half. Management characterized the remaining guide as allowing sequential growth rather than extrapolating Q2’s acceleration. [S3][S4][S13]

FFRCT is the first growth pillar. It remains applicable to a subset of CCTA studies with intermediate anatomical disease, which management estimates at roughly one-third of scans. Guideline acceptance and the maturing 2025 account cohort support volume. Q2 management commentary said FFRCT volume was substantially ahead of plan and average selling price modestly exceeded internal expectations. That does not negate the filing’s year-over-year price/mix pressure: a result can exceed a conservative plan while remaining below the previous year’s realized level. [S2][S13]

Plaque is the second and more variable pillar. Plaque revenue rose from approximately $1.5 million in all of 2025 to $3.2 million in Q1 and $7.8 million in Q2 2026. The new code, account activation, physician education, and broader applicability support growth. Management estimates Plaque can apply to approximately 60% of CCTA scans and could eventually become larger than FFRCT. Those applicability and long-run size statements are management claims. The economic tests are repeat ordering, net collection, account retention, realized price after contractual step-ups, and incremental contribution. [S13][S14]

Plaque’s first-year growth may include evaluation and reimbursement release. A provider can try the service once a code improves payment visibility, but sustained economics require repeat use after the novelty period. The July 2026 Cleerly clearance also means the first full reimbursement year overlaps with more credible direct competition. Plaque can remain a powerful Heartflow growth product without the code becoming proprietary. [S10][S11]

Workflow products form the third pillar. RoadMap can seed paid analyses, and PCI Navigator can place Heartflow nearer the intervention decision. The company launched PCI Navigator more broadly in 2026, but management has no current separate reimbursement plan. The return is therefore indirect: higher engagement, more cross-sell, greater retention, or more defensible contracts. These outcomes require matched-account proof. Otherwise, free products consume R&D and support resources without incremental revenue. [S2][S13]

Automation is the fourth pillar and primarily affects margin and capacity. Algorithm improvements have already lowered processing cost and supported gross-margin expansion. Management targets a mid-term non-GAAP gross margin near 85% and broader autonomous processing in 2027. Automation can reduce labor, shorten turnaround, and improve consistency. It also creates validation and oversight requirements, and prior gains do not guarantee equal future improvements. Investors should pair labor efficiency with error, resubmission, turnaround, complaint, and regulatory metrics. [S1][S13]

Longitudinal plaque management is a fifth option. Plaque Tracker could support comparisons over time, potentially moving Heartflow from a one-time decision tool toward chronic disease monitoring. The attraction is recurring analyses from previously studied patients. The uncertainty is whether clinicians order serial CCTA, whether radiation and contrast considerations limit frequency, whether payers reimburse repeat analysis, and whether management changes improve outcomes. No material revenue should be assumed before ordering and coverage evidence appears.

High-risk asymptomatic populations are the most speculative option. The three planned randomized studies address calcium-score patients, prior MI or PCI, and previously detected plaque. Management believes existing technology may not require new FDA clearance, but device clearance and reimbursement are separate gates. The planned endpoints emphasize changes in decisions and intermediate measures; payers may require harder clinical or economic outcomes. The base operating analysis should assign no near-term revenue to the claimed $6 billion adjacency. [S14]

International expansion is another option rather than a near-term driver. The company has non-U.S. regulatory experience, but revenue has become more U.S.-concentrated as domestic reimbursement improves. Each country requires separate market access. Management’s focus on U.S. investment reinforces the conclusion that international diversification will be gradual. [S1][S14]

The product outlook is favorable for FFRCT and Plaque over the next two years, while PCI workflow, autonomous processing, serial plaque tracking, and asymptomatic screening remain options whose revenue or margin contribution is not yet demonstrated. The appropriate sequencing is to judge 2026-2027 on current-market execution and treat distant markets as contingent upside.

Near-term catalysts include finishing above raised guidance, sustained Plaque revenue and activations, broader commercial coverage, contractual Plaque price increases, stable FFRCT price, successful automation, additional peer-reviewed evidence, and visible post-stock-compensation operating leverage. Longer-term catalysts include trial enrollment, useful decision and clinical endpoints, guideline inclusion, and payer action. Each has an offset: a higher 2026 base creates harder comparisons, shared coverage benefits rivals, price increases can test elasticity, and intermediate trial endpoints may not satisfy payers.

Verdict: The near-term growth pipeline is visible and supported by account maturation, CCTA adoption, Plaque reimbursement, and product breadth. The strongest contrary evidence is that cases are growing faster than dollars, FFRCT still concentrates revenue, free workflow modules lack demonstrated monetization, Cleerly’s clearance raises direct pressure, and the largest adjacencies require studies and reimbursement that may not arrive before 2030. [S2][S11][S14]

Financial Quality

The income statement shows strong gross-profit scaling but no consolidated profitability. Revenue rose from $87.2 million in 2023 to $125.8 million in 2024 and $176.0 million in 2025. Gross profit rose from $58.1 million to $94.4 million and $135.2 million, while gross margin expanded from 66.6% to 75.1% and 76.8%. The $77.1 million increase in gross profit on $88.9 million of additional revenue from 2023 to 2025 implies an incremental gross margin of approximately 86.8%. [S1]

Operating expense consumed the gross-profit gain. Sales, general and administrative expense increased from $95.1 million in 2023 to $134.3 million in 2025; R&D increased from $35.9 million to $64.9 million. Operating loss improved in 2024 but widened from $61.2 million to $64.1 million in 2025 despite $40.7 million of additional gross profit. Growth investment can explain the pattern, but it cannot be treated as demonstrated operating leverage. [S1]

Net loss contains financing noise. The 2025 net loss of $116.8 million included approximately $43.9 million of noncash warrant-remeasurement expense associated with pre-IPO financing. Excluding the mark is appropriate when comparing ordinary operations, but not when assessing the economic dilution and financing history that produced it. Normalized operations remained materially loss-making. [S1][S5]

Q2 2026 improved gross economics. Revenue was $64.1 million, gross profit $53.2 million, and GAAP gross margin 83.0%. GAAP operating loss was $17.9 million and net loss $15.7 million. Management reported non-GAAP operating loss of $7.9 million and adjusted EBITDA loss of $6.7 million. The gap mainly reflects stock compensation and litigation expense. These expenses may be excluded to study cash cost or legal comparability, but stock compensation transfers value and patent litigation is currently a real cost of defending the franchise. [S2][S3]

Q1 included a $7.5 million impairment arising from revised facility use and expected sublease income. Removing it helps forecast continuing operations, but the loss records a genuine capital-allocation outcome. The resulting first-half operating loss of $47.4 million should not be annualized mechanically because of the impairment and seasonal working capital, yet it confirms that high gross margin has not crossed into GAAP profit. [S2][S4]

Heartflow is not at a cyclical earnings high or low in the conventional sense; it is in a structural scale-up phase in which revenue and gross margin are rising while deliberate R&D and commercial spending keep earnings below breakeven. Healthcare utilization, elective imaging, interest rates, and hospital budgets can add cyclicality, but current earnings are driven more by penetration and reinvestment than by a mature business cycle.

Cash flow has improved over the annual history but remains negative. Operating cash use was $76.4 million in 2023, $69.0 million in 2024, and $54.0 million in 2025. After approximate capital expenditure, free-cash-flow deficits were $82.5 million, $73.4 million, and $59.0 million. First-half 2026 operating cash use was $38.7 million and capex approximately $3.8 million, producing an approximate $42.5 million deficit. Working capital, bonuses, and seasonality prevent a simple doubling, but the burden remains material. [S1][S2]

Net income and operating cash flow diverge chiefly because warrant remeasurement, depreciation, stock compensation, impairment, and working-capital movements are noncash or differently timed; cash burn remains negative even after those reconciliations. In 2025 the warrant mark made net loss materially worse than cash use. In first-half 2026, accounts receivable increased as revenue accelerated, absorbing cash. Stock compensation improves cash conversion relative to GAAP earnings while diluting shareholders. [S1][S2]

ROIC requires discipline. Conventional accounting ROIC is negative because operating profit and NOPAT are negative. The IPO conversion and debt repayment also reset the equity and invested-capital base, making pre- and post-IPO comparisons discontinuous. A research-adjusted measure would capitalize some historical R&D, add amortization, and increase invested capital, but it would also add back current expensed research; the direction and magnitude are assumption-sensitive. With only three years of comparable public statements and a cumulative deficit above $1.1 billion, quoting a precise research-adjusted percentage would imply false precision.

Business profitability is promising at the gross-profit level but absent at the consolidated level: GAAP ROIC is negative, research-adjusted ROIC is too assumption-sensitive to quote precisely, and the approximately 87% 2023-2025 incremental gross margin is the strongest evidence of potential future returns. The most useful forward test is post-stock-compensation incremental operating profit divided by cumulative operating and research investment. [S1][S2]

Accounting is conservative in several respects. Most R&D is expensed as incurred, leaving internally created algorithms, evidence, and data off the balance sheet. Revenue is recognized on delivery rather than from unfulfilled future orders. The company maintains a full valuation allowance against deferred tax assets, avoiding recognition of tax benefits whose realization is uncertain. These treatments depress current book profit and assets relative to an economically successful future platform. [S1]

Other policies require judgment. Heartflow capitalizes certain internal-use software and contract-acquisition or fulfillment costs and amortizes them. Useful lives, recoverability, and classification influence timing. The facility impairment demonstrates that recoverability estimates can change. Non-GAAP results exclude recurring stock compensation and, beginning in 2026, current patent-litigation expense, making them less conservative for per-share valuation.

Accounting is conservative in expensing most R&D and maintaining a full tax valuation allowance, but non-GAAP results are less conservative because they remove recurring stock compensation and currently recurring patent-litigation expense. Investors should use GAAP to preserve shareholder costs, then separately identify unusual financing marks and impairments rather than accepting a single adjusted denominator. [S1][S3]

The physical asset requirement is low. Annual capex was only approximately $5 million in 2025. That enables high incremental gross margin and reduces replacement-capex risk. The broader economic capital requirement is much larger: software engineering, clinical trials, regulatory submissions, payer evidence, sales coverage, and cumulative operating losses financed the platform.

Physical capital intensity is low—2025 capital expenditure was only about $5.0 million—but clinical studies, software development, regulatory work, sales coverage, and accumulated operating losses make economic capital intensity much higher than property spending suggests. A sales multiple that ignores continuing evidence and commercial investment can overstate software-like economics. [S1]

Off-balance-sheet risk is manageable but not zero. The June 10-Q showed approximately $32.3 million of undiscounted operating-lease payments and a recorded lease liability of approximately $27.1 million. Purchase commitments were approximately $6.6 million over three years. Royalty obligations, clinical studies, legal costs, compliance work, and cloud commitments also consume resources. The company reported no SEC-defined off-balance-sheet arrangements, but that term does not eliminate ordinary commercial obligations.

Material economic obligations outside funded debt include approximately $32 million of undiscounted lease payments, $6.6 million of purchase commitments, minimum and variable royalties, clinical-study commitments, and the uncapped cost of litigation and regulatory compliance. The legal exposures are not recognized as fixed liabilities because probability and amount cannot yet be estimated. [S1][S2]

Liquidity is strong. At June 30, cash and cash equivalents were $34.4 million, short-term investments $128.2 million, and long-term investments $84.3 million, totaling $246.8 million. The company had no funded debt after repaying term facilities with IPO proceeds. Current assets materially exceeded current liabilities. This balance sheet provides time for investment and legal defense, but annual cash deficits and dilution can erode it. [S2]

Dilution is material. Shares outstanding increased from 85.28 million at December 2025 to 86.72 million at June 2026, about 1.7% in six months; 86.95 million were outstanding at July 31. First-half stock compensation was approximately $14.5 million, or 12.4% of revenue. At June 30, 27.24 million shares were reserved for future issuance in total, including 9.72 million underlying options, 1.84 million underlying RSUs, and 15.69 million of ungranted plan capacity. The draft’s description of the full 27.24 million as unused plan capacity would overstate that specific component. [S2]

Verdict: Financial quality is improving in revenue, gross margin, annual cash use, liquidity, and leverage. The adverse evidence is negative GAAP ROIC, continued post-stock-compensation losses, working-capital absorption, significant potential dilution, and non-GAAP measures that exclude recurring shareholder and legal costs. [S1][S2][S3]

Capital Allocation

Heartflow’s record is venture-financed organic reinvestment followed by an IPO balance-sheet repair. Before the offering, preferred equity, convertible notes, warrants, and term debt funded product development, evidence generation, reimbursement work, and commercialization. The IPO base offering raised approximately $316.7 million gross, and exercise of the underwriters’ option increased total net proceeds to approximately $332.4 million after costs. [S1][S21]

The company used proceeds to remove financial leverage. It repaid approximately $55 million plus $5.8 million of fees on one facility and $60.1 million plus interest on another. Convertible notes with approximately $98.3 million principal converted into about 6.47 million common shares at $15.20, reflecting the contractual IPO discount. Preferred securities converted, warrants were exercised or reclassified, and the common-equity base expanded materially. [S1][S2]

The result was prudent from a solvency perspective: $246.8 million of liquidity and no funded debt at June 2026. The cost was dilution. Capital allocation must therefore be evaluated per diluted share, not by revenue growth or enterprise value alone. A debt-free company can still destroy per-share value if operating burn and equity awards persist without earning adequate returns.

Free cash flow remains negative—approximately negative $59 million in 2025 and negative $42.5 million in the first half of 2026 after capital expenditure—and management is using liquidity primarily for R&D, clinical evidence, sales expansion, automation, and operating runway. Management targets cash-flow profitability around mid-2028. That target is a measurable claim, not an achieved outcome. [S1][S2][S13]

R&D is the largest strategic reinvestment category. It reached $64.9 million in 2025 and $47.9 million in the first half of 2026. The portfolio includes Plaque, automation, PCI Navigator, Tracker, and asymptomatic trials. Shared source images and installed accounts create plausible platform economies. Returns remain unobservable because product development cost, acquisition cost, retention, and fully allocated product contribution are not disclosed.

No significant acquisition was disclosed in the reviewed filing history, so acquisition returns are not a meaningful part of Heartflow’s record; capital allocation has been overwhelmingly organic. Retrieved rules concerning acquired in-process research are therefore inapplicable to current Heartflow statements. Future acquisitions remain possible, but no value or cost should be assumed without a transaction. [S1][S2][S20]

The company has no public-market repurchase program. There was, however, a March 2023 repurchase of 102,739 shares from an employee for approximately $0.9 million, accompanied by stock-compensation accounting. That was a private compensation-related transaction, not a discretionary shareholder-return program.

Heartflow has no public-market repurchase program; the only identified repurchase was a March 2023 purchase of 102,739 shares from an employee for approximately $0.9 million, a compensation-related transaction rather than shareholder capital return. Accordingly, management receives no credit for public-market buyback timing or price discipline. [S1]

No dividend has been declared. Heartflow has declared no dividend and offers no current dividend coverage; retained liquidity is being used to finance growth and the path to cash breakeven. This is economically appropriate while free cash flow is negative. The security should not be valued on income or dividend yield. [S1][S2]

Equity compensation is the more important shareholder distribution. First-half stock compensation was $14.5 million, shares rose 1.7% in six months, and the total reserve for outstanding and future equity issuance was 27.24 million shares. The annual-plan evergreen can add capacity, subject to board action and plan terms. Not every reserved share will be issued or become dilutive, but ignoring the reserve would overstate per-share value.

Insider filings distinguish grants, exercises, withholding, and sales. CEO John Farquhar sold 22,562 shares at approximately $28.31 in August under a Rule 10b5-1 plan adopted in September 2025 and made additional planned sales later in August as the price rose. CFO David Jansen sold shares in early September under a plan adopted in June 2026. These are planned open-market sales, not option grants, tax withholding, or discretionary purchases. [S18][S19]

Equity issuance to employees is material, and reviewed post-IPO filings through September 11, 2026 show grants, exercises, withholding, and planned sales—but no identified open-market insider purchase. Planned selling does not prove weak conviction, because executives diversify and pay taxes. The absence of a purchase is nevertheless weaker confirmatory evidence than an affirmative discretionary buy. [S18][S19][S20]

Compensation emphasizes growth and product execution. CEO base salary increased to $700,000 after the IPO with a target bonus equal to 100% of salary. The 2025 bonus framework considered revenue, gross margin, product development, and quality; the board retained discretion, and the corporate score produced payouts at approximately 112.2% of target. Long-term awards primarily use options and RSUs. [S6]

Executive compensation uses salary, annual cash incentives, and long-term equity; 2025 bonuses considered revenue, gross margin, product development, and quality objectives, with board discretion and no explicit disclosed ROIC or free-cash-flow-per-share metric. The measures align management with adoption, product delivery, and regulated quality, but do not directly penalize dilution or require a return on cumulative research capital. [S6]

The CEO received large post-IPO equity awards, including options struck near the $19 offering price and RSUs. At the report-date price, those options contain substantial value. Long-term equity can align executives with appreciation, but options can reward multiple expansion and revenue growth without requiring positive ROIC. RSUs transfer value even if returns are below the cost of capital.

Management’s behavior implies a strong preference for category investment and platform breadth over near-term profit, while the incentive framework gives more explicit weight to revenue, gross margin, product milestones, and quality than to post-dilution ROIC. That preference can be value-creating if installed workflows produce retained, attractively priced analyses; it can destroy value if spending subsidizes a contestable category. [S2][S6]

The $7.5 million facility impairment is a modest but relevant allocation datapoint. Revised space needs and weaker sublease economics caused a real loss despite the asset-light model. It does not define management’s record, but it demonstrates that fixed commitments and growth plans can outlive their assumptions. [S2]

Verdict: Repaying debt and preserving liquidity were prudent, and organic reinvestment is strategically coherent. The counterweight is substantial dilution, no demonstrated product-level return, incentives weighted toward growth rather than per-share cash returns, planned insider selling without an identified open-market purchase, and a facility decision that produced an impairment. [S2][S6]

Changes and Headwinds — Last Two Years

Heartflow changed from a private, leveraged, preferred-equity-funded company into a public common-equity issuer with no funded debt. It expanded Plaque, launched additional workflow tools, grew cases and accounts, and raised gross margin above 80% quarterly. Public status also introduced quarterly expectations, visible dilution, additional controls, litigation disclosure, and exposure to valuation swings. [S1][S2]

The operating environment changed materially through stronger CCTA adoption, Category I Plaque reimbursement, rapid office and clinic expansion, new direct competitors, and evolving CMS software-payment policy. Most changes expand the addressable category while making share, price, and reimbursement policy more consequential. Cleerly’s July 2026 FDA clearance is the clearest new competitive change since the IPO. [S9][S11][S22]

Internally, algorithmic and workflow improvements reduced processing cost and increased gross margin. The commercial organization added 340 U.S. accounts in 2025 according to management, and earlier cohorts continued to mature. Plaque shifted from approximately $1.5 million of 2025 revenue to $11.0 million in the first half of 2026. R&D rose to support automation, longitudinal products, PCI tools, and trials. [S1][S13][S14]

Externally, guidelines, CCTA growth, and reimbursement expanded the funnel. The FUSION publication strengthened the clinical evidence. The new Plaque code made provider economics more legible. Conversely, office and clinic mix, rebates, and multiple analyses per scan caused case growth to outrun revenue. Shared codes and rival clearances mean the reimbursement tailwind is not exclusive.

Recent results reflect both external tailwinds and internal execution: guidelines and reimbursement expand the funnel, while account additions, utilization ramps, product launches, and processing automation determine Heartflow’s capture and margin. A purely macro explanation ignores Heartflow’s execution; a purely company-specific explanation ignores category reimbursement and CCTA growth. [S3][S8][S13]

The IPO was the largest financial change. It converted preferred and note claims, repaid more than $115 million of term borrowings and fees, removed interest and refinancing risk, and expanded the common share base. Warrant remeasurement distorted 2025 net loss around the transition. The post-IPO balance sheet is safer, but ROIC and equity comparisons across the transition require a pro forma bridge. [S1][S2]

Markets and facilities changed as well. Office-based imaging increased as a percentage of U.S. cases. Management consolidated or reconsidered facilities, generating the $7.5 million impairment. John Farquhar remained CEO, and the company reported 843 employees at year-end 2025. Public governance includes a classified board and emerging-growth-company accommodations subject to statutory thresholds. [S1][S2][S6]

Important changes in markets, facilities, and management include the 2025 IPO, expansion into office-based imaging, the facility consolidation that caused a $7.5 million impairment, and the transition to public-company governance under the continuing leadership of CEO John Farquhar. Leadership continuity reduces transition risk, while public reporting and controls add cost. [S2][S6]

Legal conditions worsened. In October 2025 Heartflow and certain employees received civil investigative demands from the DOJ Civil Division. The investigation concerns financial and contractual arrangements with healthcare providers and sales and marketing practices under the False Claims Act and Anti-Kickback Statute. No reserve, charge, timetable, or finding has been disclosed. The company’s statement that such matters can take years and are not distracting operations is management’s assessment. [S1][S2][S13]

In April 2026 Heartflow sued Cleerly over six patents. The litigation confirms direct competitive overlap and management’s intent to use intellectual property defensively. It also creates recurring expense, management attention, invalidity risk, and uncertainty over available remedies. No adjudication has established infringement or exclusivity. [S2]

Accounting policies were broadly stable. The important comparability changes arise from the IPO, warrant and preferred-security accounting, the facility impairment, and management’s exclusion of patent-litigation expense from non-GAAP results. Previously reported material weaknesses had been remediated before the end of 2024, but ongoing public-company control execution remains relevant. [S1][S2][S3]

No material accounting-policy change was identified in the last two years; the important comparability issues are IPO-related warrant and preferred-security accounting, a facility impairment, and management’s 2026 decision to exclude patent-litigation costs from non-GAAP measures. These are presentation and transition issues rather than evidence of a new revenue-recognition policy. [S1][S3]

Guidance revisions were favorable. Initial 2026 revenue guidance of $218-$222 million increased to $228-$232 million after Q1 and $246-$250 million after Q2. Repeated raises support execution confidence while increasing the comparison base for 2027. The August stock reaction shows that guidance now carries significant valuation consequences. [S3][S4][S16]

The filing review covers the available public-company history: the IPO prospectus and registration record, every available post-IPO 10-Q and 10-K, material 8-Ks, the proxy, and Forms 3, 4, and 5 through the report date. Heartflow did not have a five-year SEC periodic-reporting history; the prospectus supplies audited 2023-2024 context. [S20][S21]

Verdict: Business risk declined through reimbursement, evidence, funding, product breadth, and processing efficiency, while equity risk increased through valuation, competition, legal exposure, dilution, and harder guidance comparisons. The DOJ inquiry and Cleerly clearance are the most material adverse changes that a momentum-only reading can miss. [S2][S11]

Risk Analysis

The risk profile is asymmetric. Strong liquidity makes near-term insolvency unlikely, but a premium sales multiple capitalizes several years of growth before consolidated profitability. The principal downside is a valuation reset caused by slower growth, weaker price, competitive losses, reimbursement changes, or failure to convert gross profit into post-dilution cash flow.

Stock-decline factors include slower CCTA growth, weaker Plaque retention, falling realized price, competitor account wins, reimbursement cuts, margin slippage, adverse legal developments, cash-burn acceleration, dilution, or simple compression of a premium sales multiple. Revenue need not decline for the stock to fall sharply. A change from approximately 16 times current-year sales to the high-single-digit range would overwhelm considerable fundamental growth. [S2][S16]

The DOJ matter is the hardest non-valuation risk to quantify. A civil investigative demand is not a finding of wrongdoing. The absence of a charge after less than a year is not exculpatory either. The investigation reaches arrangements and practices near revenue generation, creating possible monetary, conduct, monitoring, reimbursement, or reputational consequences. Exclusion from federal programs would be an extreme rather than base outcome, but it illustrates why the matter cannot be treated as ordinary legal noise. [S1][S2]

Patent litigation creates two-sided variance. A favorable judgment or settlement could reinforce differentiation, impose royalties, or constrain Cleerly. A finding of non-infringement, invalidity, or easy design-around would weaken a perceived barrier. Even a successful case may not prevent competition based on different algorithms or clinical claims. Legal spending is likely to persist before the strategic result is known.

Product risk is less binary than drug-development risk because FFRCT and Plaque are already commercial, but failures can still be nonlinear. Relevant modes include accuracy degradation, inappropriate automation, poor image-quality handling, biased performance, longer turnaround, data loss, clinician distrust, recall, or a regulator demanding additional validation. Expansion into asymptomatic populations raises the burden because broad use can produce downstream testing and requires clearer benefit-risk evidence.

Reimbursement risk operates through coding, coverage, documentation, payment, and customer economics. A code does not guarantee every claim is paid or that the provider retains enough value after Heartflow’s charge. Commercial criteria and MAC policies vary. CMS can revise relative values and site-of-service treatment. A reduction in provider economics may lower orders or force vendor concessions even without formal loss of coverage. [S9][S22]

Concentration is modest at the customer level, with no customer above 10%, but system and payer decisions can have broad reach. A large health system can standardize many sites, and a regional MAC or national commercial payer can affect a significant population. The absence of a 10% customer should not be interpreted as absence of policy concentration. [S1][S2]

Liquidity reduces the probability of forced financing. It does not protect against long-term erosion. If free cash flow remained near the 2025 deficit, the current liquid resources would cover several years before considering working capital, legal costs, or financing inflows. A slower-growth business could cut spending, but that could also weaken product and commercial momentum. Options and employee plans provide financing through dilution rather than free economics.

A catastrophic investment loss would most plausibly require a combination of reimbursement impairment, serious product or fraud findings, competitive displacement, and continued spending that destroys the liquidity runway. No ordinary quarterly miss is likely to eliminate enterprise value, but a legal or regulatory impairment combined with a premium multiple could cause a very large loss. [S1][S2]

Near-term total-loss probability is low because Heartflow held about $246.8 million of liquid assets and no funded debt, but a multi-year path exists through regulatory exclusion or product failure, collapsing revenue, persistent cash burn, and repeated dilutive financing. The balance sheet buys time; it does not make an indefinitely uneconomic business valuable. [S2]

Other risks include dependence on third-party cloud infrastructure, compatibility with scanner and image protocols, international privacy rules, specialized personnel, payer audits, and limitations on tax assets after ownership changes. These matter, but valuation, reimbursement, competition, legal exposure, and dilution are currently more load-bearing.

Verdict: Solvency risk is low while drawdown risk is high. Cash and clinical relevance disconfirm an imminent-failure thesis, but neither protects shareholders from multiple compression, lost pricing, an adverse DOJ resolution, or a combined reimbursement and competitive shock. [S2][S11]

Valuation Discussion

Valuation starts with a current capital bridge. At $48.08 and approximately 86.95 million shares outstanding, equity value is approximately $4.18 billion. June cash and investments totaled $246.8 million. Adding approximately $27.1 million of operating-lease liabilities as debt produces a lease-adjusted enterprise value near $3.96 billion; excluding leases produces approximately $3.94 billion. There was no funded borrowing. [S2][S16]

Trailing revenue through Q2 2026 was approximately $212.1 million: $46.3 million in Q3 2025, $49.1 million in Q4, $52.6 million in Q1 2026, and $64.1 million in Q2. Lease-adjusted EV therefore equals approximately 18.7 times trailing revenue. Against the $246-$250 million 2026 range, it equals approximately 15.9-16.1 times. Earnings, EBITDA, free-cash-flow, and ROIC multiples are not meaningful because the denominators are negative. [S2][S3][S5]

Public peers are imperfect because no direct coronary-analysis rival publishes comparable financial statements:

Heartflow deserves a premium to mature equipment and imaging-service companies because it is growing faster and has higher incremental gross margin. Hinge Health and Doximity already show positive operating profitability, while Tempus has a much larger revenue base. The table does not supply a mechanical fair multiple; it establishes that Heartflow’s premium depends on sustained exceptional execution rather than healthcare-software membership. [S16]

Own-history valuation is not statistically robust. Heartflow has only thirteen months of public prices, and the business changed rapidly after Plaque reimbursement. Nevertheless, the August 35.7% price gap raised the sales multiple much faster than the revenue denominator. Any pre-Q2 assertion that HTFL was inexpensive became stale immediately and must be recomputed.

A twelve-month analytical framework uses 2027 revenue because near-term EBITDA remains sensitive to discretionary investment. The base estimate is approximately $328 million, or 32% growth from the 2026 guidance midpoint. This is an analyst estimate, not company guidance. A 10-times sales multiple produces $3.28 billion of enterprise value; adding approximately $220 million of estimated net cash and dividing by 90 million estimated diluted shares produces approximately $38.90 per share. The framework still grants a substantial premium while allowing growth to normalize and dilution to continue.

Longer-horizon scenarios make the embedded assumptions visible:

The bear case assumes CCTA remains relevant but FFRCT price and office mix pressure persist, Plaque slows after its reimbursement launch, competition limits share, and operating spending remains high. A 10% free-cash-flow margin still recognizes a viable business; the damage comes from slower growth, dilution, and multiple normalization.

The base case assumes current-market penetration, durable FFRCT use, meaningful Plaque cross-sell, gross margin in the mid-80s, and gradual operating leverage. It includes continued dilution and does not capitalize the $6 billion asymptomatic adjacency as assured revenue. An 18% terminal free-cash-flow margin is attractive but below mature software leaders because clinical evidence, regulation, and selling costs persist.

The bull case assumes Heartflow becomes the default CCTA analytical layer, preserves payer and evidence advantages, retains strong product pricing, automates processing, and limits dilution as cash flow turns positive. A 25% terminal free-cash-flow margin and 10-times terminal sales multiple require near-software economics. The outcome is possible but leaves little room for legal, competitive, or reimbursement friction.

The current price itself implies aggressive revenue. Assuming 96 million 2030 shares, approximately $150 million of terminal net cash, an 11% discount rate, and an eight-times terminal sales multiple, the current quote implies approximately $860 million of 2030 revenue, or about 36% annual growth from the 2026 midpoint. At a 10-times multiple, implied revenue is approximately $690 million, or about 29% annual growth. These are reverse-valuation estimates, not forecasts.

Margin conversion is as important as revenue. An 83% gross margin does not establish a 20%-25% free-cash-flow margin. Clinical trials, regulatory updates, sales coverage, payer evidence, public-company expense, litigation, and stock compensation must grow slower than gross profit without weakening the franchise. If operating losses fail to narrow as revenue passes $300-$350 million, the high incremental gross margin is being consumed rather than harvested.

Dilution affects every scenario. The current basic share count understates outstanding options, RSUs, future plan capacity, and annual employee grants. Not every reserved share should be included immediately, but a model that holds shares flat while stock compensation remains above 10% of revenue would be internally inconsistent. Faster cash profitability and smaller grants would increase per-share value; continued option and RSU issuance would transfer part of enterprise growth to employees.

The balance sheet deserves credit once. Cash reduces financing risk and adds equity value, but it was raised through equity issuance and will decline while free cash flow remains negative. Option exercises can add both cash and shares. Lease and legal costs should remain in a conservative bridge.

What the market gets right is rapid category growth, clinical evidence, the Plaque reimbursement step, gross-margin progress, and low balance-sheet risk. What is fragile is the assumption that these facts guarantee retained share, durable price, and high post-dilution returns. The most sensitive variables are 2027-2030 growth, Plaque repeat use, FFRCT price and mix, operating expense scaling, terminal multiple, and share count.

Verdict: A premium to mature imaging companies is justified, but approximately 16 times current-year revenue requires continued category-leading growth and substantial margin conversion. The disconfirming evidence against a simplistic bearish case is 45% first-half growth and 83% Q2 gross margin; the disconfirming evidence against the current premium is negative post-stock-compensation profit and healthcare-software references at roughly half the sales multiple. [S2][S16]

Variant Perception

The apparent market view is that Heartflow leads a large, underpenetrated CCTA-analysis category; Plaque reimbursement creates a second engine; evidence, integrations, and data form a durable moat; and gross margin above 80% will eventually produce software-like cash margins. The 35.7% post-Q2 move and current peer premium are consistent with that view, although no formal positioning survey is available. [S3][S16]

The strongest bull case is that Heartflow becomes the default analytical layer for coronary CCTA. Guideline adoption expands the number of scans, the 2025 account cohort matures, FFRCT remains durable, Plaque adds another paid analysis to the same scan, and free RoadMap and PCI tools increase workflow dependence. Automation then moves gross margin toward the mid-80s, while evidence, payer work, and patents prevent rivals from matching trust and access. Operating expense grows slower than gross profit, producing high free-cash-flow margins.

The strongest bear case is not product failure. It is that Heartflow created a valuable category without securing exclusive economics. Vendor-neutral codes attract Cleerly, Keya, Elucid, and future vendors. Providers multi-source or negotiate more aggressively. Office mix and rebates lower realized price. Cases grow faster than unique scans and revenue. Heartflow continues funding studies, sales, and litigation while stock compensation dilutes shareholders. Revenue can remain impressive while the multiple compresses before free cash flow arrives.

The central variant perception separates achievements that the current valuation tends to bundle together. Clinical utility is not the same as hard-outcome benefit. Coverage is not proprietary reimbursement. Cases are not patients. Data scale is not monopoly economics. Gross margin is not ROIC. Heartflow has strong evidence on the first concept in each pair and incomplete evidence on the second.

Thoughtful investor questions on the latest call and conference focused on why Plaque is winning, whether competitors are taking share, how average selling price evolves, why second-half guidance is conservative, when operating leverage appears, what endpoints will support asymptomatic reimbursement, and what the DOJ and patent matters could mean. Management supplied activation, utilization, pricing, and category arguments but did not disclose independent share, product retention, paid-claim economics, or a legal resolution. [S13][S14]

Five assumptions are load-bearing:

1. CCTA continues taking share from established tests. Guidance and expert consensus support the modality. A sustained decline in CCTA volume at active accounts or materially weaker guideline support would falsify this premise. [S8]

2. Heartflow preserves category leadership. Installed workflows, evidence, and payer history support the assumption. Cleerly’s July clearance, Keya’s predicate pathway, and shared codes challenge exclusivity. Independent account loss, multi-sourcing, or matched-account decline would falsify the strong version. [S10][S11][S12]

3. Plaque becomes retained cross-sell rather than a reimbursement spike. Q2 revenue and activations are supportive. The test is repeat ordering and net revenue per activated account after the first-year anniversary and contractual price changes. [S13]

4. Gross-margin leverage reaches per-share cash returns. Q2’s 83% gross margin is strong. Failure to narrow post-stock-compensation operating loss as revenue passes $300-$350 million would challenge the model. [S2]

5. Legal matters remain containable. No adverse finding has been announced. A material reserve, settlement restricting provider arrangements, payer reaction, patent invalidation, or continuing legal expense without competitive benefit would change the economics. [S1][S2]

The factor model is a dated statistical risk diagnostic, not an industry classification. As of September 10, 2026, Market exposure was 1.02 and SmallSize exposure 1.11. Residual momentum was slightly negative at -0.04, residual Sharpe was -0.16, and residual volatility was high at 0.76. The model’s R-squared was only 0.108, so the included factors explained about 11% of return variation. Its small sector coefficients must not be interpreted as Heartflow’s legal or economic sector. [S15]

Low explanatory power is consistent with a short-history, event-driven stock. Q2 produced a 35.7% one-day move, while two other double-digit declines lacked clean primary catalysts. Small-size and market exposure can amplify broad risk appetite, but most observed variability remains idiosyncratic within the model. The model cannot establish that recent appreciation was fundamental alpha.

Retrieved research learnings were tested rather than imported. Acquired-IPR&D rules are inapplicable because no significant acquisition was disclosed. The general warning that record counts do not establish monopoly economics is directionally useful, but Heartflow’s regulated image data differ from contributed-data businesses and require company-specific evidence. The rule that a large price gap requires a fresh valuation calculation is confirmed by the August re-rating. A company-specific learning about AI-adopter correlations was not transferred because its original scope and mechanism do not match diagnostic ordering closely enough.

The freshest contradiction to an inherited moat narrative is Cleerly’s July 2026 plaque clearance. The freshest contradiction to an inherited cheapness narrative is the August price gap. The strongest confirmation of business quality is the simultaneous 48% revenue growth and 83% gross margin. The strongest unresolved bridge is whether these achievements produce retention and post-dilution cash returns.

Verdict: The differentiated view is not that Heartflow lacks a good product. It is that the stock prices category leadership as durable economic ownership before independent share, product retention, pricing, claim collection, and post-dilution returns are disclosed. The bull case prevails if those bridges appear without a material slowdown. [S2][S11][S16]

Fact vs. Interpretation

Several apparent conflicts can be resolved without choosing the most favorable wording. Plaque had some access across all seven MAC regions, but only five had final favorable policies and two were case by case. Management can say FFRCT price was above internal plan while aggregate revenue per case falls year over year because the comparison, product mix, and channel mix differ. An 83% gross margin is fully consistent with negative ROIC because research, sales, evidence, compliance, litigation, and stock compensation sit below gross profit. [S1][S2][S13]

Verdict: Reported operating momentum is real. The contested inference is whether momentum establishes exclusive market power, durable net price, and high returns per diluted share. [S2][S11]

Open Questions

1. What were FFRCT and Plaque paid analyses, gross billings, rebates, denials, and net revenue separately by quarter?

2. How many unique patients and unique CCTA scans generated Q2’s 84,491 cases, and how often did one scan generate two counted analyses?

3. What are one-, two-, and three-year retention and utilization curves for the 2024 and 2025 account cohorts?

4. How many accounts use a competing advanced CCTA-analysis vendor, and what are measured win and loss rates against Cleerly and other named competitors?

5. What portion of Plaque activation represents repeat ordering after the first several reimbursed cases rather than initial evaluation?

6. What are actual collection and denial rates under each MAC and major commercial payer, rather than estimates of covered lives?

7. How much of the expected early-2027 Plaque price increase is contractually fixed, and what attrition or volume elasticity is assumed?

8. What percentage of each product is processed autonomously, how does automation affect turnaround and error rates, and what additional validation is required?

9. What development and commercial spending will the three asymptomatic trials require through a reimbursement decision?

10. Which endpoints would change payer policy for asymptomatic use, and what happens if studies show decision changes without hard outcomes or lower cost?

11. What provider financial and contractual arrangements fall within the DOJ demands, and have selling practices changed?

12. What annual patent-litigation cost should be expected, and what outcomes could materially restrict Cleerly rather than prompt a design-around?

13. What mature post-stock-compensation operating margin does management target, and what annual dilution is embedded in mid-2028 cash-flow profitability?

14. How much of the 15.69 million ungranted plan capacity is likely to be granted over the next three years, and what forfeiture and exercise assumptions apply to outstanding awards?

15. What portion of capitalized software and contract costs relates to current products versus products whose commercial return remains uncertain?

16. How will potential loss of emerging-growth-company accommodations affect audit cost, controls, and the timing of operating leverage?

17. Can management reconcile billing-address geography in the 10-Q to the operational geography presented in the earnings release?

These are the disclosures needed to distinguish category growth from company economics and enterprise-value growth from value per share. The questions arise directly from case definitions, legal disclosures, reimbursement variation, and equity-plan data. [S1][S2][S13]

What Must Be True

For the bull case to be right:

• 2027 revenue must remain above approximately 30% growth, with both durable FFRCT utilization and retained Plaque cross-sell contributing after the reimbursement anniversary. The current base is strong—first-half 2026 growth was 45%—but that makes the comparison demanding. [S2][S3]

• Product-adjusted realized pricing must stabilize. Falling consolidated revenue per case is acceptable only if unique-scan growth, product mix, and fully allocated gross profit per scan improve. The filing already identifies office mix and rebates as pressure. [S2]

• Plaque must produce repeat ordering and attractive net collection across activated accounts after evaluation use and planned contractual price changes. A shared code and Cleerly’s current clearance make account retention more informative than gross activations. [S10][S11][S13]

• Gross margin must remain approximately 82%-85% without deterioration in turnaround, accuracy, image acceptance, or regulatory performance. Q2’s 83.0% GAAP result establishes the starting evidence. [S2]

• R&D and SG&A must grow materially slower than gross profit, and post-stock-compensation operating loss must narrow as revenue approaches $300-$350 million. Historical gross-profit growth has not yet produced consolidated profit. [S1][S2]

• Annual dilution must moderate. Shares increased 1.7% in six months and first-half stock compensation was 12.4% of revenue, so enterprise growth does not automatically become per-share growth. [S2]

• Direct competitors must fail to take material installed accounts, payer preference, or net price despite obtaining clearances and using shared codes. Heartflow’s evidence and workflow advantages must become visible in retention or independently verifiable share. [S7][S10][S11]

• The DOJ matter must resolve without penalties or restrictions that materially change provider arrangements, selling practices, reimbursement, or federal-program access. [S1][S2]

• Asymptomatic trials must produce endpoints that payers and guidelines consider decision-useful. Diagnostic information or treatment changes alone may be insufficient if no clinical or economic benefit follows. [S14]

Bull falsifiers are measurable: growth below 25% before cash profitability; declining FFRCT revenue at matched accounts; weak Plaque repeat use; gross margin below 80%; failure to narrow post-SBC operating loss above $350 million revenue; annual share growth above 5%; meaningful competitive displacement; or an adverse DOJ resolution.

For the bear case to be right:

• Category reimbursement must prove less proprietary than the valuation assumes, allowing multiple vendors to achieve coverage and narrow the evidence or workflow gap. Vendor-neutral codes and the Cleerly clearance make this plausible but do not yet prove share loss. [S10][S11]

• Case growth must continue outrunning revenue because of multiple products from one scan, lower-priced channels, rebates, or competition. Q2 provides one clear observation, not a sufficient long-term trend by itself. [S2]

• Heartflow must require sustained high research and selling expense to defend share, preventing high gross margin from converting to cash flow. Operating loss remained $64.1 million in 2025 despite revenue growth. [S1]

• The market must normalize the terminal sales multiple before profitability offsets the change. Current valuation is materially above profitable and larger healthcare-software references. [S16]

• Legal or regulatory costs must remain material, or the DOJ and patent matters must alter selling conduct, reimbursement, or competitive protection. [S1][S2]

Bear falsifiers are equally concrete: independently verified share gains; stable product-level prices; strong multi-year account retention; rising Plaque net revenue per activated account after its anniversary; four consecutive quarters of positive post-SBC operating leverage; cash-flow profitability ahead of mid-2028; annual dilution below 2%; and patent or comparative-outcome evidence that prevents rivals from obtaining equivalent payer access.

The monitoring dashboard should contain unique scans and patients if disclosed, product-level cases and net revenue, retained Plaque accounts, channel mix, gross margin, GAAP operating loss, stock compensation as a percentage of revenue, operating cash use, diluted shares, competitor clearances and coverage, DOJ language, patent rulings, and trial milestones. A thesis should change when those measures change, not when management repeats a market-size estimate. The most authoritative continuing records are Heartflow’s annual filing, June 2026 quarterly filing, the FDA’s Cleerly clearance record, and the FUSION clinical publication.

Public source appendix

• S1: Heartflow 2025 Annual Report on Form 10-K — primary_filing; published 2026-03-18; Items 1, 1A, 7 and 8; financial statements; Notes 2-17; revenue, reimbursement, liquidity, equity compensation, leases, legal proceedings and repurchase disclosure
• S2: Heartflow Quarterly Report on Form 10-Q for June 30, 2026 — primary_filing; published 2026-08-13; Condensed financial statements; Notes 2-14; MD&A; case definition and history; liquidity, leases, commitments, legal proceedings and equity-plan reserves
• S3: Heartflow Second-Quarter 2026 Financial Results — primary_company_release; published 2026-08-13; Quarterly highlights, revised 2026 guidance, Plaque guidance and GAAP/non-GAAP reconciliation
• S4: Heartflow First-Quarter 2026 Financial Results — primary_company_release; published 2026-05-14; First-quarter operating highlights, Plaque revenue and first increase to 2026 guidance
• S5: Heartflow Quarterly Report on Form 10-Q for September 30, 2025 — primary_filing; published 2025-11-12; Q3 financial statements, warrant remeasurement, revenue and post-IPO liquidity
• S6: Heartflow 2026 Definitive Proxy Statement — primary_filing; published 2026-04-29; Executive and director compensation, incentive metrics, equity awards, ownership and governance
• S7: FUSION Randomized Trial of CCTA With Selective FFRCT — peer_reviewed_clinical_study; published 2026-08-27; Abstract, methods, results and conclusions; 528 randomized patients and reported 90-day and one-year outcomes
• S8: SCCT and SCAI Expert Consensus on CCTA-Derived Fractional Flow Reserve — professional_consensus; published 2026-06-04; Patient selection, clinical role, image-quality requirements, evidence review and vendor-neutral recommendations
• S9: CMS Calendar Year 2026 Physician Fee Schedule Final Rule — government_rulemaking; published 2025-11-05; Final CY2026 physician payment policy and applicable coding and payment materials
• S10: Cleerly 2026 Reimbursement Guidelines — competitor_material; publication date unavailable; CPT 75577 and 75580 coding and provider-level 2026 Medicare reimbursement information
• S11: FDA 510(k) Record for Cleerly Plaque — regulatory_record; published 2026-07-29; K261210 decision record, device classification and substantial-equivalence determination
• S12: FDA 510(k) Summary for Keya Medical DeepVessel FFR — regulatory_record; published 2022-04-01; Intended use, technological characteristics, performance and Heartflow FFRct predicate
• S13: Company Financials — Heartflow Second-Quarter 2026 Earnings-Call Transcript — management_transcript; published 2026-08-13; August 13, 2026 prepared remarks and analyst questions on guidance, Plaque, competition, ASP, automation, legal matters and cash profitability
• S14: Heartflow at the Wells Fargo 21st Annual Healthcare Conference — management_conference_transcript; published 2026-09-09; September 9, 2026 management discussion of market size, Plaque, coverage, asymptomatic trials, U.S. investment and competition
• S15: The factor model — HTFL statistical exposure snapshot — quantitative_diagnostic; published 2026-09-10; Exposures, residual signals and diagnostics dated September 10, 2026
• S16: Company Financials — HTFL and peer market snapshot — third_party_financial_data; published 2026-09-11; NASDAQ:HTFL resolution; September 11, 2026 price; public price history; enterprise value, trailing financials and exchange-qualified peer data
• S17: Heartflow Announces FDA Clearance and Launch of Next-Generation Plaque Analysis — primary_company_release; published 2025-09-22; Next-generation Plaque clearance, launch and Cigna coverage effective October 1, 2025
• S18: Heartflow Form 4 — John Farquhar — primary_insider_filing; published 2026-08-12; August 2026 open-market sale and Rule 10b5-1 footnote
• S19: Heartflow Form 4 — David Jansen — primary_insider_filing; published 2026-09-04; September 2026 open-market sales and Rule 10b5-1 footnote
• S20: SEC Filing History for Heartflow — regulatory_filing_index; publication date unavailable; Registration statements, prospectus, 10-K, all available 10-Qs, material 8-Ks, proxy and Forms 3, 4 and 5 through September 11, 2026
• S21: Heartflow Announces Pricing of Initial Public Offering — primary_company_release; published 2025-08-07; Offering price, base share count, gross proceeds, underwriters’ option and Nasdaq trading date
• S22: CMS Calendar Year 2027 Physician Fee Schedule Proposed Rule — government_rulemaking; published 2026-07-16; Proposed CY2027 physician payment policy; proposal status and comment timetable